Related Experiment Video

Updated: Mar 5, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Do the Side Effects of BRAF Inhibitors Mimic RASopathies?

Alicia Sfecci1, Alain Dupuy2, Monica Dinulescu1

  • 1Department of Dermatology, Pontchaillou Hospital, CHU de Rennes, Rennes, France.

The Journal of Investigative Dermatology
|March 26, 2017
PubMed

Insights

Targeted cancer therapies, like BRAF inhibitors, cause side effects distinct from chemotherapy. These drug-induced skin conditions (iatrogenic dermatoses) strikingly resemble genetic skin disorders (genodermatoses) in RASopathies.

Area of Science:

  • Oncology
  • Dermatology
  • Genetics

Background:

  • Targeted anticancer therapies offer improved cancer prognoses but have unique side effects.
  • These side effects differ from traditional chemotherapy and stem from interference with specific oncogenic signaling pathways.
  • Pathway interference can lead to effects mimicking genetic disorders.

Purpose of the Study:

  • To compare the clinical effects of BRAF inhibitor treatment with genetic RASopathies.
  • To investigate the overlap between drug-induced dermatoses and genodermatoses.

Main Methods:

  • Clinical comparison of side effect profiles.
  • Analysis of BRAF inhibitor-induced dermatoses.
  • Comparison with congenital RASopathies and their associated genodermatoses.

Main Results:

  • A striking overlap was observed between iatrogenic dermatoses from BRAF inhibitors and genodermatoses in RASopathies.
  • Targeted therapies can induce effects mirroring congenital genetic disorders.

Conclusions:

  • Understanding the link between targeted therapy side effects and genetic disorders deepens insight into drug mechanisms.
  • This comparison aids in better understanding and managing side effects of novel cancer treatments.

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.8K
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

9.1K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.9K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K